Company announces IV rigosertib did not meet primary endpoint of significantly improved survival versus best supportive care in higher-risk myelodysplastic syndromes

Results of Phase 3 trial demonstrated that in the intent-to-treat analysis, patients randomised to IV rigosertib (a phosphatidylinositol 3 kinase inhibitor) achieved overall survival of 6.4 months vs. 6.3 months for physician's choice (p=0.33) in overall population.


Biospace Inc.